Cytokinetics, Inc. — Q3 2014 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014. Cytokinetics is a clinical-stage biopharmaceutical company developing muscle-function therapies; it had no commercial drug sales.
Financial results and liquidity
- Revenue: Q3 revenue was $9.4 million, up from $4.5 million a year earlier. Nine-month revenue was $25.2 million, versus $6.3 million. Revenue primarily came from collaboration research reimbursements and recognition of the Astellas license fee, not product sales.
- Losses and expenses: Q3 operating loss was $6.0 million and net loss was $6.0 million ($0.16 per share), compared with operating loss of $12.6 million and net loss of $12.6 million ($0.43 per share) in Q3 2013. Nine-month operating loss was $23.2 million and net loss was $23.1 million ($0.65 per share), versus $40.3 million and $40.2 million ($1.52 per share), respectively, in 2013. No income tax benefit was recorded.
- Operating expenses: Q3 R&D was $11.4 million, down from $13.4 million; G&A was $4.0 million, up from $3.6 million. Nine-month R&D was $35.6 million in both years; G&A rose to $12.7 million from $11.0 million. Product gross margin is not applicable because there were no commercial sales.
- Cash flow: Nine-month operating cash use was $36.7 million, compared with $4.7 million provided in 2013, reflecting ongoing operations and a $10.9 million reduction in deferred revenue. Investing activities used $10.4 million; financing provided $39.8 million, principally from the February public offering.
- Liquidity and capital: Cash, cash equivalents and investments totaled $82.5 million at September 30, 2014, versus $80.2 million at year-end 2013. The company reported $12.9 million cash and cash equivalents, $65.6 million short-term investments and $4.0 million long-term investments. It raised $37.5 million net in a February 2014 stock offering and about $2.4 million through its at-the-market program. Outstanding common shares increased to 36.6 million from 30.7 million at year-end.
- Debt and commitments: The balance sheet lists no borrowing balance; operating lease commitments totaled $13.5 million, with the facility lease expiring in 2018. Total liabilities were $13.6 million, including deferred revenue.
Material changes and business developments
- Revenue growth reflected higher Astellas collaboration activity and license revenue recognition, as well as increased Amgen reimbursements. The Astellas agreement contributed $14.1 million of R&D revenue and $7.6 million of license revenue in the first nine months; Amgen contributed $3.4 million of related-party R&D revenue.
- Q3 R&D expense fell mainly with lower outsourced clinical and skeletal-muscle program spending, partly offset by higher cardiac-program spending. Nine-month R&D was flat as lower clinical and other program costs offset increased preclinical, personnel and cardiac-program costs.
- In February 2014, the company issued 5.0 million shares in a public offering. The MLV at-the-market program reached its share limit in January.
- In April 2014, the company reported that tirasemtiv’s BENEFIT-ALS Phase IIb trial did not meet its primary ALSFRS-R endpoint. It did show a statistically significant reduction in decline in Slow Vital Capacity (SVC); the company considered the finding potentially clinically meaningful. In October, after the quarter, it said it was planning a potential Phase III trial and had begun FDA discussions; FDA acceptance of SVC as an endpoint remained uncertain.
- Also after quarter-end, the company reported completion of five Phase I studies of CK-2127107, with results described as generally well tolerated and supportive of further development planning. Amgen’s COSMIC-HF oral omecamtiv mecarbil study was enrolling; management expected enrollment to conclude by year-end 2014.
Outlook, risks and unusual items
- 2014 guidance: Revenue of $29–31 million; R&D expense of $47–50 million; and G&A expense of $18–21 million. Management expected R&D and G&A to increase versus 2013.
- Management expected available cash, cash equivalents and investments to fund projected requirements for at least 12 months from the filing’s reporting date, while anticipating continued operating losses and cash outflows. It may need additional collaboration funding, equity or debt financing; financing may be unavailable or dilutive or restrictive.
- The company’s principal programs were tirasemtiv (ALS and other neuromuscular disorders), CK-2127107 (with Astellas, for non-neuromuscular muscle weakness indications) and omecamtiv mecarbil (with Amgen, for heart failure). Development depends in part on partner decisions, clinical outcomes, regulatory acceptance, funding and manufacturing.
- BENEFIT-ALS had a study-drug assignment programming error affecting 58 patients, leading to a protocol amendment, additional enrollment, costs and delay. The company stated it intended to seek damages from its data-management vendor. No legal proceedings were reported; management said it knew of no indemnification matter expected to materially affect the company.
- Other key risks include the failed primary BENEFIT-ALS endpoint, tirasemtiv adverse events and withdrawals, uncertain clinical and regulatory outcomes, partner control over partnered programs, lack of product revenue, and potential limits on use of tax-loss carryforwards under Section 382.
Most important facts for investors to verify
- Whether FDA feedback supports SVC as a Phase III endpoint for tirasemtiv, and the design, funding and timing of any Phase III trial.
- Whether the $82.5 million liquidity position and stated 12-month runway remain adequate given operating cash use and forecast spending.
- Progress, enrollment and results for COSMIC-HF and CK-2127107’s next development steps, including partner funding and decisions.
- Whether 2014 revenue and expense guidance was achieved, and how much reported revenue represented recurring reimbursements versus license-fee recognition or milestones.
- The status and potential outcome of the company’s intended claim against its data-management vendor, and the effect of share issuance, warrants and options on dilution.